[Epidemiology of Cutaneous Leishmaniasis in West Africa: a Systematic Review]. / Épidémiologie de la leishmaniose cutanée en Afrique de l'Ouest : revue systématique.

Cutaneous leishmaniasis (CL) has been described in West Africa (WA) since the beginning of the 20th century. The incidence of cases has markedly increased during the last decades in several countries of the region. Despite that, data remain scarce and fragmentary. The current incidence and geographic distribution of the disease as well as the involved vectors and reservoirs remain poorly documented. The objective of this review was to collect and analyze available data about CL in WA in order to improve the management of cases and the control of the disease transmission. A systematic literature review was performed using the Pubmed, Google Scholar and Hinari databases. Publications focusing on epidemiological aspects of CL, involved parasite species, sand flies and potential reservoir hosts were searched without any restrictions. Unpublished studies were extracted from Google. Manuscripts without full text or summary available were excluded as well as those whose summaries did not contain any usable data. One hundred and fifteen studies were recorded. Among them, 93 filled selection criteria. CL has been reported in 10 West African countries with outbreaks described in five countries. Burkina Faso, where the average incidence of the disease is around 928 cases per year, and Ghana seem to be the most affected. Cases have been confirmed in the majority of studies by microscopy sometimes associated with culture or histology. The exposure rate to Leishmania infection based on leishmanin skin test was relatively high with an overall average of 30.2%. Leishmania major was the only species identified with a predominance of MON-74 (62%) and MON-26 (30.6%) zymodemes. Phlebotomus duboscqi is retained as the vector whereas Sergentomyia darlingi and Sergentomyia ingrami were found naturally infected. Rodents including Arvicanthis niloticus, Gerbilliscus gambiana and Mastomys spp. are reported as the main reservoir hosts. Additional studies are needed to better characterize CL in WA in order to optimize the management of cases and to organize the control of the disease transmission.

La leishmaniose cutanée (LC) est décrite en Afrique de l'Ouest (AO) depuis le début du xxe siècle. Les dernières décennies ont été marquées par une augmentation franche de l'incidence des cas dans plusieurs pays de la région. Les données restent cependant rares et fragmentaires. Ainsi, l'incidence et la distribution géographique réelles ne sont pas connues, et les vecteurs et réservoirs impliqués sont largement hypothétiques et peu documentés. L'objectif de cette revue était de collecter et d'analyser les données et les connaissances disponibles dans la région en vue de mieux aborder la prise en charge et le contrôle de la maladie. Une revue systématique de la littérature a été effectuée à l'aide des bases de données Pubmed, Google Scholar et Hinari. Les publications portant sur les aspects épidémiologiques de la LC, les parasites en cause, les phlébotomes et les potentiels réservoirs de parasite ont été recherchées sans aucune restriction. Les études non publiées ont été extraites sur Google.com. Les articles sans texte intégral ou résumé disponibles ont été exclus ainsi que ceux dont les résumés ne contenaient aucune donnée exploitable. Cent quinze études ont été recensées dont 93 ont été retenues. La LC a été rapportée dans dix pays de l'AO. Des foyers épidémiques ont été décrits dans cinq pays. Le Burkina Faso où l'incidence moyenne est d'environ 928 cas par an et le Ghana semblent les plus touchés. Les cas de LC ont été souvent confirmés par la microscopie, associée parfois à la culture ou à l'histologie. Les taux d'exposition à l'infection par Leishmania établis par intradermoréaction à la leishmanine étaient élevés avec une moyenne de 30,2 %. Leishmania major a été la seule espèce identifiée avec une prédominance des zymodèmes MON-74 (62 %) et MON-26 (30,6 %). Phlebotomus duboscqi en est retenu le vecteur, sachant que Sergentomyia darlingi et Sergentomyia ingrami ont été trouvées naturellement infectées. Les muridés Arvicanthis niloticus, Gerbilliscus gambiana et Mastomys spp. en seraient par ailleurs les principaux réservoirs. Des études complémentaires écologiques et en population générale sont nécessaires pour mieux caractériser la LC et son cycle de transmission en AO afin de mieux en organiser la prise en charge, voire la lutte.

[Onchocerciasis in Burkina Faso: a Re-Emerging Vector-Borne Endemic Disease]. / Onchocercose au Burkina Faso : une endémie à transmission vectorielle en voie de réémergence.

Burkina Faso, like other countries, reported a focal interruption of onchocerciasis transmission and was thus placed under post-therapeutic surveillance. However, the country seems to be experiencing a resurgence of the disease according to recent surveys at certain sentinel sites and data from various surveys. The aim of our study is to take stock of the evolution of the current epidemiological situation of onchocerciasis in Burkina Faso. For data collection, in addition to the scientific articles, we have used data from different epidemiological and entomological surveys conducted by the National Program for the Control of Neglected Tropical Diseases (PNLMTN) through its onchocerciasis elimination unit in Burkina Faso. Prior to implementation of the Onchocerciasis Control Program in West Africa (OCP), Burkina Faso had onchocerciasis prevalence between 60% and 80%. In 2002, the maximum prevalence dropped to 15%. However, in 2010 and 2011, epidemiological surveys indicated that some villages in the Comoé River basin had prevalence rate ranging from 0.7% to 71%. Thirteen (13) villages had prevalence rates above the tolerable threshold of 5%. Despite the implementation of the community-directed treatment with ivermectin (CDTI) since 2011, recent surveys show a tendency for a recrudescence of the disease in some sites, yet covered by the TIDC. This suggests that the elimination of onchocerciasis requires the integration of new control strategies. Thus, an essential condition for the elimination of onchocerciasis is the analysis of the situation in each focus in order to define the most cost-effective strategy for permanently interrupting the transmission of the parasite. National onchocerciasis elimination committees put in place will play a key role in determining the best strategy.

Le Burkina Faso, comme d'autres pays, avait signalé une interruption focale de la transmission de l'onchocercose et était ainsi placé sous surveillance post-thérapeutique. Cependant, le pays semble connaître une résurgence de la maladie selon les récentes enquêtes au niveau de certains sites sentinelles et les données de diverses enquêtes. Le but de notre étude est de faire le point sur l'évolution de la situation épidémiologique actuelle de l'onchocercose au Burkina Faso. Pour la collecte des données, nous nous sommes servis, en plus des articles scientifiques, des données des différentes enquêtes épidémiologiques et entomologiques menées par le Programme national de lutte contre les maladies tropicales négligées (PNLMTN) au travers de son unité d'élimination de l'onchocercose au Burkina Faso. Avant la mise en oeuvre du Programme de lutte contre l'onchocercose en Afrique de l'Ouest (Onchocerciasis Control Programme in West Africa), le Burkina Faso enregistrait des prévalences de l'onchocercose comprises entre 60 et 80 %. En 2002, la prévalence maximale a chuté à 15 %. Cependant, en 2010 et 2011, des enquêtes épidémiologiques indiquent que certains villages du bassin de la Comoé avaient des prévalences allant de 0,7 à 71 %. Treize villages avaient des prévalences supérieures au seuil tolérable de 5 %.Malgré la mise en place du traitement à l'ivermectine sous directives communautaires (TIDC) depuis 2011, les récentes enquêtes montrent une tendance à la recrudescence de la maladie dans certains sites, pourtant couverts par le TIDC. Cela suggère que l'élimination de l'onchocercose nécessite l'intégration de nouvelles stratégies de lutte. Ainsi, une condition essentielle pour l'élimination de l'onchocercose est l'analyse de la situation dans chaque foyer afin de définir la stratégie la plus rentable pour interrompre de manière permanente la transmission du parasite. Les comités nationaux d'élimination de l'onchocercose mis en place joueront un rôle clé dans la détermination de la meilleure stratégie.

Prevalence of vulvovaginal candidiasis in pregnancy at three health centers in Burkina Faso.

INTRODUCTION: Pregnant women are more susceptible to vaginal colonization and infection by yeast. The role of Candida colonization in the occurrence of preterm birth is well established. The knowledge of local epidemiology and identification of risk factors for preterm birth is important for the prevention and management strategies. The purpose of the study was to determine the prevalence of Candida sp. in vaginal swabs of pregnant women. METHODS: Pregnant women attending routine antenatal visits in three primary health centres in Bobo-Dioulasso (Burkina Faso) were enrolled into a cross-sectional study carried out from February to April 2015. Vaginal swabs samples were taken from participants after obtaining oral consent. The swabs were inoculated into Sabouraud's glucose agar supplemented with chloramphenicol and incubated at 37°C for 24 to 48hours under aerobic conditions in order to perform fungal culture. The identification of the Candida species was done by culture on HiCrome Candida Differential Agar at 35°C for 48h for production of species-specific colors. RESULTS: A total of 229 pregnant women were included. The prevalence of vulvovaginal candidiasis (VVC) was 22.71%, (95% CI [17.45-28.69]). Candida albicans accounted for 40.39% and non-Candida albicans species for 59.61% of the isolates, with mainly C. glabrata (32.69%), C. tropicalis (15.38%) and C. krusei (11.54%). CONCLUSIONS: This study revealed a high prevalence of non-C. albicans species. The syndromic management guidelines for VVC in Burkina Faso will be revised to include a specific protocol for pregnant women.

In vitro susceptibility of Candida albicans clinical isolates to eight antifungal agents in Ouagadougou (Burkina Faso).

INTRODUCTION: In recent years, the infection Candida albicans infection worldwide has risen, and the incidence of resistance to traditional antifungal therapies is also increasing. The aim of this study was to evaluate in vitro susceptibility of C. albicans clinical isolates to eight antifungal agents in Ouagadougou. MATERIALS AND METHODS: A cross-sectional study was conducted from January 2013 to December 2015 at Yalgado Ouédraogo University Teaching Hospital. Two hundred seven strains have been isolated from 347 symptomatic patients received in different clinical services. Samples were cultured on Sabouraud Dextrose Agar supplemented with Cloramphenicol. Isolates were diagnosed as C. albicans using germ tube test, chlamydospore formation on Corn Meal Agar, and Api-Candida test (Biomérieux). Antifungal susceptibility testing was performed by disk diffusion method and isolates classified as susceptible, susceptible dose-dependent and resistant. RESULTS: Three hundred forty-seven (347) patients are included in this study. Two hundred and six (206) out of 347 collected samples (59.36%) were found positive for C. albicans. The strains were mostly isolated from vulvovaginal (49%) and oral infections (40.3%). The highest resistance rates of azoles were obtained with fluconazole (66.5%), itraconazole (52.3%) and ketoconazole (22.9%) when all clinical isolates were included. The resistance rates of fluconazole, itraconazole and ketoconazole remain highest for vulvovaginal and oral isolates. The rate of resistance to the polyene amphotericin B was 32.0% for all clinical isolates and was 56.4% for vulvovaginal strains. Resistance rate to nystatin was 6.3% for all clinical isolates. Cross-resistance analysis with data of all clinical strains revealed that the incidence of resistance to ketoconazole and itraconazole in fluconazole-resistant isolates was significantly higher than recorded for fluconazole-susceptible isolates. CONCLUSION: In vitro C. albicans antifungal susceptibility test in this study showed relatively high resistance to commonly and widely used azoles (fluconazole, ketoconazole). Most C. albicans clinical isolates were susceptible to nystatin.

[A case of rhinofacial entomophthoromycosis in Soudano-Sahelian tropical climate in Burkina Faso]. / Un cas d'entomophthoromycose rhinofaciale en climat tropical soudano-sahélien au Burkina Faso.

We describe a rhinofacial entomophthoramycosis case in a sexagenarian (65 years old) housewife. She was immunocompetent and resident of Burkina Faso. She consulted both the service of dermatology and the service of stomatology of the Teaching Hospital of Bobo-Dioulasso in February 2016 for a diffuse facial tumefaction evolving over six months. This tumefaction was associated with headaches and a left nasal obstruction. Histological examination of the lesion showed an important and polymorphic inflammatory reaction. Also, a filamentous fungus with wide non-septated hyphae and right-angled fungal branching, consistent with mucormycosis was isolated. Mycological diagnosis based on fungal culture with Sabouraud medium without any antibiotic and cyclohexemide after incubation at 27°C and at 30°C was negative. Furthermore, it was not possible to amplify the DNA extracted from biopsy. Antifungal therapy based on the administration of fluconazole per os at 800mg/day was started allowing clinical improvement. This is the first case of a rhinofacial entomophtharomycosis documented in Bobo-Dioulasso. Rhinofacial entomophthoromycosis is largely unknown, even in tropical regions such as Burkina Faso. This lack of knowledge results in a delay in the diagnosis, and subsequently a bad prognosis. It is therefore urgent to improve knowledge on this disease to guide diagnostic steps, prognosis of outcome, and antifungal therapy.

Anti-Candida albicans natural products, sources of new antifungal drugs: A review.

INTRODUCTION: Candida albicans is the most prevalent fungal pathogen in humans. Due to the development of drug resistance, there is today a need for new antifungal agents for the efficient management of C. albicans infections. Therefore, we reviewed antifungal activity, mechanisms of action, possible synergism with antifungal drugs of all natural substances experimented to be efficient against C. albicans for future. METHODS: An extensive and systematic review of the literature was undertaken and all relevant abstracts and full-text articles analyzed and included in the review. REVIEW: A total of 111 documents were published and highlighted 142 anti-C. albicans natural products. These products are mostly are reported in Asia (44.37%) and America (28.17%). According to in vitro model criteria, from the 142 natural substances, antifungal activity can be considered as important for 40 (28.20%) and moderate for 24 (16.90%). Sixteen products have their antifungal activity confirmed by in vivo gold standard experimentation. Microbial natural products, source of antifungals, have their antifungal mechanism well described in the literature: interaction with ergosterol (polyenes), inhibition 1,3-ß-d-glucan synthase (Echinocandins), inhibition of the synthesis of cell wall components (chitin and mannoproteins), inhibition of sphingolipid synthesis (serine palmitoyltransferase, ceramide synthase, inositol phosphoceramide synthase) and inhibition of protein synthesis (sordarins). Natural products from plants mostly exert their antifungal effects by membrane-active mechanism. Some substances from arthropods are also explored to act on the fungal membrane. Interestingly, synergistic effects were found between different classes of natural products as well as between natural products and azoles. CONCLUSION: Search for anti-C. albicans new drugs is promising since the list of natural substances, which disclose activity against this yeast is today long. Investigations must be pursued not only to found more new anti-Candida compounds from plants and organisms but also to carried out details on molecules from already known anti-Candida compounds and to more elucidate mechanisms of action.

[Epidemiological aspects of cutaneous mycosis of HIV-infected patients in the National Referral Center of Burkina Faso, West Africa]. / Aspects épidémiologiques des mycoses cutanéo-phanériennes chez les patients infectés par le VIH au Centre national de référence du Burkina Faso, Afrique de l'Ouest.

AIM: Our study aimed to analyze the epidemiological aspects of cutaneous mycosis in people living with human immunodeficiency virus (PLHIV). MATERIALS AND METHODS: This is a descriptive study of 382 patients living with HIV. Following an investigation into the risk factors, mycological samples have been performed. Each sample underwent direct examination and cultivation for the identification of fungal species. The Blastese test is used for the identification of Candida albicans. RESULTS: One hundred and six (106) of the 382 people living with human immunodeficiency virus undergo a mycological collection of which 76 gave a positive result. The overall prevalence of cutaneous mycosis was 19.9 %. It was significantly higher in women and in patients who had a CD4 count ≤500/mm3. C. albicans and Trichophyton rubrum were the most isolated species with 22.4 and 19.8 % of all fungal species isolated, respectively. CONCLUSION: Cutaneous mycoses are common among people living with human immunodeficiency virus and whose CD4 count ≤ 500/mm(3).

[Epidemiological and etiological aspects of superficial fungal infections among prison inmates in Ouagadougou, Burkina Faso]. / Aspects épidémiologiques et étiologiques des mycoses cutanéo-phanériennes chez les détenus de la maison d'arrêt et de correction de Ouagadougou (Burkina Faso).

OBJECTIVE: The fight against fungal infections in prisons is within the overall framework of the fight against these diseases in the general population. To contribute to the fight against these diseases, we conducted this study among inmates of the big prison of Ouagadougou. It aimed to analyze the epidemiological and etiological aspects of superficial fungal infections among prison inmates in Ouagadougou. MATERIALS AND METHODS: It was a matter of an analytical descriptive study (December 2011-April 2012) that examined 212 selected using a stratified sampling detainees. It consisted firstly of a survey on risk factors. Secondly, samples were taken from prisoners with suspicious lesions of superficial mycoses. For each lesion, some fragments were examined directly between slide and coverslip in KOH (10% or 30%). The remaining fragments were cultured on Sabouraud-Chloramphenicol and Sabouraud-Chloramphenicol-Actidione. The media were then incubated at 27°C for 1 month before declaring any negativity. RESULTS: The overall prevalence of superficial fungal infections among prison inmates Ouagadougou was 25.5%. The recent prison inmates (≤24 months) were the most affected (89.8%). Dermatophytes (15.56%) were more isolated than non-dermatophytes (12.26%) Anthropophilic species predominated among dermatophytes: T. mentagrophytes (7.0%), T. rubrum (3.3%), M. langeronii (23%), E. floccosum (1.41%) and T. violaceum (0.94%). M. gypseum (0.47%) was the only land-based species encountered. Non-dermatophytes were Malassezia sp. (11.79%) and Candida sp. (0.47%). Polyparasitism was less represented (7.4% of infected prisoners). Several body sites were mostly infected by one fungal agent. Pityriasis versicolor was the most common fungal infection (37.31%). CONCLUSION: Considering the results, specific control measures are to be taken against the superficial fungal infections in prisons and in the general population.

Disseminated histoplasmosis caused by Histoplasma capsulatum var. duboisii in a non-HIV patient in Burkina Faso: Case report.

Histoplasmosis is a fungal infection due to Histoplasma capsulatum. The African form of this mycosis, caused by Histoplasma capsulatum var. duboisii, remains rare. We report a case of disseminated African histoplasmosis with skin, lymph nodes, bones and viscera localizations. The 22-year-old patient was HIV-seronegative and was considered immunocompetent. The presence of Histoplasma capsulatum var duboisii in ulcerations and a nodule pus aspiration was confirmed by direct microscopic examination and by culture. The medical treatment was based on fluconazole. Even though a regression of the symptoms was observed, the patient died. In disseminated African histoplasmosis, an early laboratory diagnosis must be carried out for accurate treatment.

[Intestinal parasites in prisoners in Ouagadougou (Burkina Faso)]. / Prévalence du parasitisme intestinal en milieu carcéral à Ouagadougou (Burkina Faso).

OBJECTIVES: to analyze the epidemiologic and clinical aspects of intestinal parasitosis in prisoners at the prison in Ouagadougou (MACO). MATERIALS AND METHODS: cross-sectional study from November 2009 to January 2010, including a survey to determine the risk factors and clinical signs of intestinal parasitosis. It also included laboratory examination of feces samples from 403 prisoners, by direct analysis, the Willis and Ritchie methods, and a scotch test for oxyuris (Enterobios vermicularis). RESULTS: The global prevalence of intestinal parasitosis was 71.5%. There was a link between parasitism and the prison section. Amebae were the most frequent parasites (66.7%), with high prevalence of Entamœba coli (55.6%). They were followed by flagellata (16.6%), mainly Trichomonas intestinalis (9.2%). Helminths were less frequent (7.4%). Most subjects with parasites were symptomatic (diarrhea or constipation) (p = 10(-4)). CONCLUSION: our results highlight the need to improve sanitation at the prison and provide hygiene education for the prison population.

Sratégies d'amélioration des allocations budgétaires pour la santé au Burkina Faso / Strategies for health budget allocations in Burkina Faso

Depuis les indépendances, les stratégies d'allocation budgétaire au niveau du ministère de la santé étaient basées sur l'analyse des budgets passés (allocation historique), les contraintes budgétaires générales et sur des pourcentages d'augmentation des crédits par rapport aux exercices précédents. Elles ne se fondaient pas sur les priorités des programmes. En effet, dans la pratique, la circulaire budgétaire est généralement accompagnée des montants alloués à chaque structure, calculés sur la base des allocations de l'année précédente. La mise en œuvre parfois concomitante de différents instruments ou initiatives (CDMT, PPTE, CGAB, Cadre de planification et de suivi des financements du secteur de la santé) et de différentes stratégies d'allocation budgétaire (IGR, alignement du cycle de planification à l'élaboration du budget de l'Etat, financement basé sur les résultats, budget programme) a certes contribué à accroître globalement le financement de la santé, mais les allocations budgétaires n'ont tenu compte ni des besoins des structures de santé, ni du niveau de santé de la population, ni de l'émergence et la reémergence de certaines pathologies. La conséquence qui en a résulté, est une allocation budgétaire inadaptée et repartie de manière non équitable.